| 2021 |
In September 2021, with the launch of Revital NXT, Sun Pharma Consumer Healthcare, a division of Sun Pharmaceutical Industries Ltd., announced its entry into the nutrition bar category in India. Revital NXT, is a brand extension of Revital H, a health supplement.
In June 2021, Sun Pharmaceuticals acquired the patent license for Dapagliflozin from AstraZeneca. The company will distribute and promote the drug under the brand name ‘Oxra’.
In May 2021, the company entered a royalty-free, non-exclusive licensing agreement with Eli Lilly and Company to expand access to the COVID-19 drug, Baricitinib. The company will manufacture and distribute the drug in India.
https://www.ndtv.com/business/coronavirus-medicine-covid-19-infection-drug-news-sun-pharma-gains-on-agreement-with-eli-lilly-to-make-baricitinib-in-india-2438740In March 2021, Sun Pharmaceuticals acquired a 12.5% stake in Australia-based WRS Bioproducts for US$ 1.5 million.
In February 2021, the company launched a website for its long-term care portfolio in the US, highlighting the efficacy and safety profile for each product.
In February 2021, it introduced Brivaracetam, an anti-epileptic drug, in multiple dosage forms, a day after the patent expiry. This drug was developed by UCB, a Belgian-based firm. |
